Recombinant Anti-Urokinase antibody [EPR6273] (ab133563)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR6273] to Urokinase
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Urokinase antibody [EPR6273]
See all Urokinase primary antibodies -
Description
Rabbit monoclonal [EPR6273] to Urokinase -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide within Human Urokinase aa 50-150. The exact sequence is proprietary.
Database link: P00749 -
Positive control
- WB: PC-3, LnCaP and MCF7 cell lysates. IHC-P: Human kidney tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Dissociation constant (KD)
KD = 5.19 x 10 -11 M Learn more about KD -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR6273 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Assay kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab133563 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Predicted molecular weight: 49 kDa.
For unpurified use at 1/100. |
|
IHC-P |
1/150. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000. Predicted molecular weight: 49 kDa. For unpurified use at 1/100. |
IHC-P
1/150. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Function
Specifically cleave the zymogen plasminogen to form the active enzyme plasmin. -
Tissue specificity
Expressed in the prostate gland and prostate cancers. -
Sequence similarities
Belongs to the peptidase S1 family.
Contains 1 EGF-like domain.
Contains 1 kringle domain.
Contains 1 peptidase S1 domain. -
Post-translational
modificationsPhosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 5328 Human
- Entrez Gene: 18792 Mouse
- Entrez Gene: 25619 Rat
- Omim: 191840 Human
- SwissProt: P00749 Human
- SwissProt: P06869 Mouse
- SwissProt: P29598 Rat
- Unigene: 77274 Human
see all -
Alternative names
- ATF antibody
- ATF uPA antibody
- BDPLT5 antibody
see all
Images
-
All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/100 dilution (unpurified)
Lane 1 : LnCap cell lysate
Lane 2 : PC-3 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 49 kDa
Observed band size: 49 kDaBlocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (ab133563)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling Urokinase with purified ab133563 at 1/150. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Negative control using PBS instead of primary antibody. Counterstained with Hematoxylin.
-
All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1300 dilution (purified)
Lane 1 : LnCaP cell lysate
Lane 2 : PC-3 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 49 kDa
Observed band size: 49 kDaBlocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1000 dilution (unpurified)
Lane 1 : PC-3 cell lysate
Lane 2 : LnCaP cell lysate
Lane 3 : MCF7 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 49 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (7)
ab133563 has been referenced in 7 publications.
- Huo Z et al. Hypomethylation and downregulation of miR-23b-3p are associated with upregulated PLAU: a diagnostic and prognostic biomarker in head and neck squamous cell carcinoma. Cancer Cell Int 21:564 (2021). PubMed: 34702271
- Abufaraj M et al. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urol Oncol N/A:N/A (2020). PubMed: 32381392
- Burchall GF et al. Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state. Reprod Biol Endocrinol 17:33 (2019). PubMed: 30878040
- Yang K et al. Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis. Int J Clin Oncol N/A:N/A (2019). PubMed: 30937621
- Cammalleri M et al. The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. J Cell Mol Med 23:5176-5192 (2019). PubMed: 31251468
- Zhao L et al. Alterations in complement and coagulation pathways of human placentae subjected to in vitro fertilization and embryo transfer in the first trimester. Medicine (Baltimore) 98:e17031 (2019). PubMed: 31689742
- Ye S et al. Thrombosis recanalization by paeoniflorin through the upregulation of urokinase-type plasminogen activator via the MAPK signaling pathway. Mol Med Rep 13:4593-8 (2016). WB ; Human . PubMed: 27082639